COMPARATIVE ANALYSIS OF ANTIVIRAL THERAPIES IN CHRONIC HCV PATIENTS: CLINICAL OUTCOMES AND TREATMENT IMPLICATIONS
Bulletin of Biological and Allied Sciences Research·
- DOI
- 10.64013/bbasr.v2026i1.136
- PMID
- —
- PMCID
- —
- OpenAlex
- W7208771801
- Study type
- Journal article
- Publisher
- BBASR Publishers
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Findings highlight commonly reported HCV exposure routes in this cohort, including unsafe barber visits (38.2%), unsafe therapeutic injections (31.8%), and unsafe dental procedures (24.5%), suggesting potential targets for infection control.
Structured evidence summary
Research question
The study evaluated clinical outcomes of direct-acting antiviral (DAA) regimens in chronic hepatitis C virus (HCV) patients, including demographic patterns and treatment efficacy.
Study design
A comparative treatment analysis of 110 HCV-confirmed patients classified into two DAA treatment groups, with sustained virologic response (SVR) assessed at 3 and 6 months.
Population and setting
110 chronic HCV patients, with a higher proportion of males (54.5%) than females (45.5%), predominantly from urban areas (62.7%) and most frequently aged 36–55 years (46.4%).
Main findings
Overall SVR at 24 weeks was 89.1%; sofosbuvir plus ribavirin achieved 93.2% SVR versus 84.3% for sofosbuvir plus daclatasvir. Common reported adverse effects included generalized body aches, fatigue, headache, and fever across both DAA groups.
Public-health relevance
Findings highlight commonly reported HCV exposure routes in this cohort, including unsafe barber visits (38.2%), unsafe therapeutic injections (31.8%), and unsafe dental procedures (24.5%), suggesting potential targets for infection control.
Important limitations
This summary is limited to the supplied single-article abstract/metadata; the original paper is needed for decision-grade interpretation. The abstract does not report sample-size justification, randomization, blinding, genotype distribution across arms, or statistical testing.
GIDS interpretation
Within the GIDS framework, this article is discoverable as a peer-reviewed treatment-efficacy and transmission-context study on HCV, potentially useful for editorial contextualization rather than as an active surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.